Covid-19 jab maker to build SE Asia manufacturing site

By Agence France-Presse

May 10, 2021 5:04 pm

FRANKFURT: Coronavirus jab maker BioNTech said on Monday it would build a southeast Asia headquarters and manufacturing site in Singapore to produce hundreds of millions of mRNA-based vaccines per year.

Construction of the site will start this year, and it could become operational by 2023, the German company said in a statement.

Already have an active account? Log in here to continue reading.
Or
Subscribe to the Premium Subscription plan to access this subscriber-exclusive article.